Search Results - "Kinkema, Caitlin"

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer by Eno, Meredith S., Brubaker, Jason D., Campbell, John E., De Savi, Chris, Guzi, Timothy J., Williams, Brett D., Wilson, Douglas, Wilson, Kevin, Brooijmans, Natasja, Kim, Joseph, Özen, Ayşegül, Perola, Emanuele, Hsieh, John, Brown, Victoria, Fetalvero, Kristina, Garner, Andrew, Zhang, Zhuo, Stevison, Faith, Woessner, Rich, Singh, Jatinder, Timsit, Yoav, Kinkema, Caitlin, Medendorp, Clare, Lee, Christopher, Albayya, Faris, Zalutskaya, Alena, Schalm, Stefanie, Dineen, Thomas A.

“…While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven…”
Get full text

Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors by Scheuplein, Felix, Renner, Florian, Campbell, John E., Campbell, Robert, De Savi, Chris, Eckmann, Jan, Fischer, Holger, Ge, Jie, Green, Luke, Jakob, Peter, Kim, Joseph L., Kinkema, Caitlin, McGinn, Katie, Medina, Ricardo, Müller, Annemarie, Perez, Nisha, Perola, Emanuele, Timsit, Yoav, Traore, Tary, Hopfer, Ulrike, Tyanova, Stefka, Tzouros, Manuel, Wang, Ruduan, Woessner, Richard, Dorsch, Marion, Bischoff, James R.

“…Introduction The serine/threonine kinase 17B (STK17B) is involved in setting the threshold for T cell activation and its absence sensitizes T cells to…”
Get full text